Dr. Harrison Kim, PhD

Claim this profile

University of Alabama at Birmingham

Studies Pancreatic Cancer
Studies Glioblastoma
3 reported clinical trials
3 drugs studied

Area of expertise

1

Pancreatic Cancer

Harrison Kim, PhD has run 2 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage III
Stage I
Stage II
2

Glioblastoma

Harrison Kim, PhD has run 1 trial for Glioblastoma.

Affiliated Hospitals

Image of trial facility.

University Of Alabama At Birmingham

Clinical Trials Harrison Kim, PhD is currently running

Image of trial facility.

P4 Diagnostic Tool

for Pancreatic Cancer

The goal of this study is to investigate whether the therapeutic response of pancreatic tumors can be accurately assessed using quantitative DCE-MRI, when the inter/intra-scanner variability is reduced using the Point-of-care Portable Perfusion Phantom, P4. The intra-scanner variability over time leads to errors in therapy monitoring, while the inter-scanner variability impedes the comparison of data among institutes. The P4 is small enough to be imaged concurrently in the bore of a standard MRI scanner with a patient for real-time quality assurance. The P4 is safe, inexpensive and easily operable, thus it has great potential for widespread and routine clinical use for accurate diagnosis, prognosis and therapy monitoring. This study has identified two arms, one arm is healthy individuals that will undergo DCE MRI at three different MRI locations to establish baseline results. The healthy volunteers will undergo these MRIs prior to the second arm, which contains patients with pancreatic cancer. The pancreatic cancer patients will only have DCE MRI done at one location.

Recruiting

1 award

N/A

3 criteria

Image of trial facility.

Imaging-Guided Chemotherapy

for Pancreatic Cancer

The goal of this study is to test whether chemotherapy guided by a new imaging method named DCE-MRI can more effectively reduce a pancreatic tumor, enabling curable surgery, over the conventional method when a tumor is categorized as borderline resectable pancreatic cancer. UAB radiological research team has been studying a cutting-edge imaging technique named dynamic contrast-enhanced magnetic resonance imaging, or DCE-MRI, for over 10 years. This technique has been globally used to calculate the blood flow of various tissues, including tumors. Blood flow often serves as a critical indicator showing a disease status. For example, a pancreatic tumor typically has low blood flow, so it can be used as an indicator to identify the presence of a pancreatic tumor. In addition, an effective therapy can result in the increase of blood flow in a pancreatic tumor during the early period of treatment. Therefore, the investigators may be able to determine whether the undergoing therapy is effective or not by measuring the change of blood flow in the pancreatic tumor and deciding whether to continue the therapy or try a different one.

Recruiting

1 award

N/A

More about Harrison Kim, PhD

Clinical Trial Related

3 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Harrison Kim, PhD has experience with

  • Point-of-care Portable Perfusion Phantom (P4)
  • Point-of-care Portable Perfusion Phantom, P4
  • Neoadjuvant Chemotherapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Harrison Kim, PhD specialize in?

Is Harrison Kim, PhD currently recruiting for clinical trials?

Are there any treatments that Harrison Kim, PhD has studied deeply?

What is the best way to schedule an appointment with Harrison Kim, PhD?

What is the office address of Harrison Kim, PhD?

Is there any support for travel costs?